miRNA‐155 and miRNA‐181a as prognostic biomarkers for pediatric acute lymphoblastic leukemia

El‐Khazragy, Nashwa; Noshi, Mohamed Ahmed; Abdel-Malak, Camelia; Zahran, Rasha; Swellam, Menha

doi:10.1002/jcb.27918

Cited by 34 publications

(30 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The different expression of miR‐155 may affect the prognosis and may explain the resistance to the treatment pattern of HCV genotype 4 . On the other hand, studies that investigated the role of miR‐155 in CML and AML demonstrated that it is upregulated in cells and circulating exosomes . There was a negative correlation between the expression of miR‐155 and the response to antiviral drugs; however, a positive correlation with disease progression has been observed .…”

Section: Introductionmentioning

confidence: 99%

“…14 On the other hand, studies that investigated the role of miR-155 in CML and AML demonstrated that it is upregulated in cells and circulating exosomes. 4,[15][16][17] There was a negative correlation between the expression of miR-155 and the response to antiviral drugs; however, a positive correlation with disease progression has been observed. 18,19 Patients who achieved complete remission showed low levels of miR-155 in the plasma.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

In vitro knock‐out of miR‐155 suppresses leukemic and HCV virus loads in pediatric HCV‐4–associated acute lymphoid leukemia: A promising target therapy

Hassan

El-Khazragy⃰

Elshimy

et al. 2019

J of Cellular Biochemistry

Self Cite

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is a major public health problem, having a high prevalence in Egypt. Leukemia and lymphoma have been associated with HCV infection. MicroRNA‐155 (miR‐155) has been reported to play a regulatory role in cancer, inflammation, and immune response to infection. The expression level of miR‐155 in HCV viremic patients is controversial; although high miR‐155 levels were demonstrated in HCV genotypes 1,2, and 3, low levels of miR‐155 were detected in Egyptian patients with HCV genotype 4. Several studies have investigated the correlation between the levels of miRNA‐155 and the replication of HCV, others have evaluated miRNA‐155 as a prognostic biomarker in different types of cancer. No studies have investigated the impact of miRNA‐155 knockdown on HCV pediatric patients associated with childhood acute lymphoblastic leukemia (ALL). We knocked‐out the miR_155a in cultured polymorphonuclear cells (PBMCs) obtained from 60 children with ALL; 30 were associated with HCV‐4 infection and 30 were HCV negative. The miR_155a, HCV viral load, and cell proliferation werre assessed in treated and untreated cells using TaqMan assay quantitative polymerase chain reaction. We found that miRNA‐155 was significantly upregulated by seven folds in the HCV‐4 associated ALL group; while being linked to high HCV viral load and leukemic burden, miR_155a knock‐out can improve the disease outcome. We conclude that miR‐155 is a critical miRNA that is considered a therapeutic target in pediatric HCV leukemic patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

In vitro knock‐out of miR‐155 suppresses leukemic and HCV virus loads in pediatric HCV‐4–associated acute lymphoid leukemia: A promising target therapy

Hassan

El-Khazragy⃰

Elshimy

et al. 2019

J of Cellular Biochemistry

Self Cite

View full text Add to dashboard Cite

show abstract

“…Circulating miRNAs are attractive molecules as non-invasive cancer biomarkers due to their surprising degree of stability in biological fluids. Several recent studies have demonstrated that miRNAs are stably detectable in plasma/serum [28,29,30]. MiRNA-221 and miRNA-222 are overexpressed in different types of malignant neoplasms including ovarian cancer 31, hepatocellular cancer [32], glioblastomas [33] and breast cancer [10,13,34].…”

Section: Discussionmentioning

confidence: 99%

Clinical Impact of Oncomirs 221 and 222 on Breast Cancer Diagnosis

Ahmed

El-bast

Mohamed³

et al. 2020

Asia-Pac J Oncol

Self Cite

View full text Add to dashboard Cite

Background Dysregulation of miRNAs, non-coding RNAs of 18-25 ( ̴ 22nt), is a hallmark of malignancies among them is breast cancer. The present study aimed to investigate the expression levels of circulating oncomiRNAs (miRNA-221and miRNA-222) as a minimally non-invasive method for early detection of breast cancer as compared to tumor markers (CEA, CA15.3). Materials and methods MiRNA-221 and miRNA-222 expression levels were determined using quantitative real-time polymerase chain reaction (qPCR) in serum samples from three groups: primary breast cancer patients (n = 44), benign breast lesion patients (n = 25), and healthy individuals as control group (n = 19). Their diagnostic efficacy and relation with clinicopathological data were analyzed. Results MiRNA-221 and miRNA-222 expression and tumor markers reported significant increase in their mean levels in breast cancer group as compared to the benign breast lesions or control individuals. Among clinicopathological factors, miRs reported significant relation with pathological types, clinical staging, histological grading and hormonal status, while CEA and CA15.3 did not revealed significance with these factors. The diagnostic efficacy for investigated miRNAs was superior to tumor markers especially for detection of early stages and low grade tumors. Conclusion MiRNA-221 and miRNA-222 were superior over tumor markers for early detection of breast cancer especially those at high risk as primarybreast cancer patients with early stage or low grade tumors.

show abstract

“…It has been evident that more than 10,000 discovered lncRNAs have been contributed to human solid and hematopoietic cancers [20].Adjacent with the high needs for new non-invasive diagnostic and prognostic biomarkers that target human cancer; the lncRNAs occupy the forefront of use in leukemia [19]. Recent studies provide evidence that the long non-coding RNA -HOTAIR "HOX transcript antisense RNA" has an oncogenic role in AML [2,18]; however; the precise underlying molecular mechanism still under investigations [21]. Few studies tried to determine the different pathways by which HOTAIR influence myelopoiesis; they reported that knockdown of HOTAIR blunted the expression of HOX1 and HOX4 during myeloid differentiation [19].…”

Section: Discussionmentioning

confidence: 99%

“…Micro RNAs (miRNA) are small non-coding RNA molecules, it's far composed approximately of (20-25nucleotides), they are corresponding for suppression gene expression via binding to complementary segments of messenger RNA and interfering with the formation of proteins by way of translation [13,[15][16][17][18]. According to Xing et al, miR-193a was downregulated in AML blasts because of hypermethylation in its promoter area.…”

Section: Introductionmentioning

confidence: 99%

Upregulation of HOTAIR Predicts Poor Outcome in Acute Myeloid Leukemia

Mohamed¹,

El-Khazragy⃰²,

Zaky³

2019

COR

View full text Add to dashboard Cite

Background: Acute myeloid leukemia (AML) is a clonal hematopoietic malignancy, in spite of the marked improvement in the treatment of AML; Molecular biomarkers open the door to improve disease outcome. Accumulating evidence suggested that the long non-coding RNA “HOTAIR” has an oncogenic role in hemopoietic malignancies. Recently, it has been evident that knockdown of HOTAIR inhibits cell proliferation and induces apoptosis by modulating c-Kit expression via acting as competing for endogenous RNAs (ceRNAs) to sponge miR-193a at the post-transcriptional level. Objectives: we aimed to evaluate the diagnostic and prognostic value of HOTAIR in AML, to investigate its association with and c-Kit and miR-193a. Subjects & Methods: we examined the expression levels of HOTAIR, miR-193a, and c-Kit in 100 de-novo AML patients using quantitative, the association of genes expressions with risk factors and patient’s outcome were statistically analyzed. Results: the expression of HOTAIR was significantly upregulated by four folds in AML compared to healthy controls; higher expression levels were associated with high-risk factors, poorer overall survival (OS) and shorter leukemia-free survival (LFS). In addition; a negative correlation was detected between Lnc-HOTAIR and miR-193a, although significance didn’t reach. Conclusion: The obtained results suggested that HOTAIR expression was upregulated in peripheral blood samples of de-novo AML patients and was associated with leukemic burden and disease outcome. Therefore, it may represent an effective diagnostic and poor prognostic tool for AML.

show abstract

miRNA‐155 and miRNA‐181a as prognostic biomarkers for pediatric acute lymphoblastic leukemia

Cited by 34 publications

References 17 publications

In vitro knock‐out of miR‐155 suppresses leukemic and HCV virus loads in pediatric HCV‐4–associated acute lymphoid leukemia: A promising target therapy

In vitro knock‐out of miR‐155 suppresses leukemic and HCV virus loads in pediatric HCV‐4–associated acute lymphoid leukemia: A promising target therapy

Clinical Impact of Oncomirs 221 and 222 on Breast Cancer Diagnosis

Upregulation of HOTAIR Predicts Poor Outcome in Acute Myeloid Leukemia

Contact Info

Product

Resources

About